Mythical Games Announces Launch of New Marketplace and Acquisition of DMarket
25.1.2023 15:00:00 EET | Business Wire | Press release
Mythical Games, the next-generation gaming technology studio, has launched Mythical Marketplace 2.0 following the acquisition of marketplace tech start-up DMarket, as part of its continued commitment to innovation in gaming. The new marketplace is built on Mythical’s new layer 1 EVM blockchain and powered by the Mythos native ecosystem token, MYTH. The acquisition is a significant milestone for Mythical Games, with DMarket’s tech facilitating the most advanced trading platform for digital assets. It makes Mythical the world’s second-largest processor of digital assets on a distributed ledger after the Ethereum mainnet, as of December.
Mythical’s Marketplace 2.0 has fully integrated DMarket’s technology to feature principles of its blended payment gateway, featuring a powerful AML and anti-fraud protection system built on more than a decade of industry experience. Combined with Mythical’s expertise in gaming and digital assets, Marketplace 2.0 provides a frictionless user experience that enables peer-to-peer transactions and empowerment for gamers looking to participate in the play-and-own gaming economies of the future. The Mythical Chain has been live for six weeks, processing over 2 million transactions.
“We founded Mythical Games in 2018 with the idea of ushering in both the next generation of gaming and the next generation of gamers. Half a decade later, we’re continuing to do just that. Mythical’s Marketplace 2.0 was designed to not only enhance our platform but, more importantly, improve the player experience and set the standard for the future of gaming,” said John Linden, co-founder and CEO, Mythical Games. “All too often, developers tout features as ‘seamless’ and ‘integrated’ when discussing gaming or metaverse projects. In reality, these solutions are still very complicated and not made for gamers. But with these monumental steps forward, Mythical will provide users with an experience that delivers on both.”
Marketplace 2.0 will support NFL Rivals and Nitro Nation World Tour assets, with plans to expand to all Mythical titles on the Mythical Chain. Assets on the Mythical Chain will be entirely governed by smart contracts with both ownership and commerce logic enforced on a secure distributed digital ledger.
“The new horizons of the gaming space have always been the main focus for DMarket. We’re excited to become a part of Mythical Games' work to reduce barriers to entry for innovative game developers and thriving new economies,” said Vlad Panchenko, co-founder and CEO of DMarket. “We share a vision of how the industry will evolve and how we all can contribute and bring more fun to the gaming community worldwide.”
DMarket’s office in Kyiv, Ukraine, becomes part of Mythical East, with its headquarters in Lisbon, Portugal. Its co-founders, Vlad Panchenko and Tamara Slanova, will become part of Mythical’s Executive leadership team, with a particular focus on building the best and easiest marketplace technology for the gaming industry.
DMarket has also adopted the Mythical Chain for its existing marketplace, which will continue to operate outside of the Mythical Marketplace. DMarket.com will retain the familiar experience with purchases in USD in the web experience; however, all trades are recorded on the Mythical Chain to provide full transparency to the community.
For more information on Mythical Games’ Marketplace 2.0, visit http://mythical.market.
About Mythical Platform
Mythical Platform can be added to pre-existing game economies or built into the design of a new game from the ground up, and enables management of digital asset trades, payments, users, and inventory management, making it possible for buyers and sellers of digital assets to transact confidently in an environment founded on transparency, security, trust and value. Mythical Marketplace provides seamless integration to game inventory and offers fraud protection, fee optimization, and soon asset bundling and buyer and seller pricing recommendations. Mythical partners will also have access to proprietary intelligence, market design and market intervention tools that enable easy and safe digital asset transactions.
About Mythical Games
Acknowledged by Forbes’ Disruptive Technology Companies to Watch in 2019 and Fast Company’s World Changing Ideas 2021, Mythical is a next-generation games technology company creating a gaming ecosystem by leveraging tradeable digital assets for tools that enable players, creators, artists, brands and game developers to become stakeholders and owners in new creator-focused game economies.
Led by gaming industry veterans, the team specializes in building games around player-owned economies and has helped develop major franchises, including Call of Duty, World of Warcraft, Guitar Hero, DJ Hero, Marvel Strike Force and Skylanders.
About DMarket
DMarket is the biggest marketplace for trading gaming and esports digital assets. Based on the Newzoo report, it is also one of the top three blockchain-based marketplaces worldwide. The company was founded in 2017 by serial entrepreneurs Vlad Panchenko and Tamara Slanova. DMarket's partners and customers include Darewise, GSC Game World, the Na’Vi esports team, Unity, Xsolla, and others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124006123/en/
Contact information
Nate Nesbitt
nate.nesbitt@mythical.games
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
